Analysts Offer Insights on Healthcare Companies: Advaxis (NASDAQ: ADXS) and Nektar Therapeutics (NASDAQ: NKTR)

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Advaxis (NASDAQ: ADXS) and Nektar Therapeutics (NASDAQ: NKTR) with bullish sentiments.

Advaxis (NASDAQ: ADXS)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Advaxis (NASDAQ: ADXS), with a price target of $6. The company’s shares closed yesterday at $1.76, close to its 52-week low of $1.51.

Ramakanth noted:

“Olga Smolentseva, Ph.D. – (646-975-6966) / osmolentseva@hcwresearch.com ADXS-NEO Can Incite Immune Responses With “Non-Immunogenic” Antigens; Reiterate Buy ADXS-NEO demonstrates potential in two preclinical studies. On April 16, Advaxis presented results from two preclinical studies of ADXS-NEO at the 2018 American Association for Cancer Research (AACR) Annual Meeting. Recall, ADXS-NEO is a personalized therapy targeting tumor neoantigens developed from Advaxis’ Lm-LLO listeria delivery platform. ADXS-NEO was licensed to Amgen (AMGN; not rated) in 2016 for $40M upfront and up to $475M in development, regulatory and sales milestone payments and up to mid-double-digit royalties on worldwide sales. In the first of the two studies, the company demonstrated that ADXS-NEO is able to target frameshift mutations and drive a neoantigen-specific antitumor immune response in MC38 and CT26 mouse tumor models.”

According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 2.4% and a 35.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Eleven Biotherapeutics.

Advaxis has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.

Nektar Therapeutics (NASDAQ: NKTR)

In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Nektar Therapeutics (NASDAQ: NKTR), with a price target of $125. The company’s shares closed yesterday at $93.47.

According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 2.0% and a 47.9% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Audentes Therapeutics.

Currently, the analyst consensus on Nektar Therapeutics is Strong Buy and the average price target is $105.86, representing a 13.3% upside.

In a report issued on April 13, Piper Jaffray also initiated coverage with a Buy rating on the stock with a $125 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.